KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
Artesunate is the most common treatment for malaria throughout the world. Artesunate has anticancer activity likely through the induction of reactive oxygen species, the same mechanism of action utilized in <i>Plasmodium falciparum</i> infections. Components of the kelch-like ECH-associa...
Main Authors: | Kristen S. Hill, Anthony McDowell, J. Robert McCorkle, Erin Schuler, Sally R. Ellingson, Rina Plattner, Jill M. Kolesar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/8/1885 |
Similar Items
-
Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
by: Anthony McDowell, et al.
Published: (2021-02-01) -
E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway
by: Chen, X., et al.
Published: (2022) -
The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions
by: Jingya Wang, et al.
Published: (2021-01-01) -
The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment
by: Keiko Taguchi, et al.
Published: (2021-12-01) -
Identification of novel indole derivatives acting as inhibitors of the Keap1–Nrf2 interaction
by: Barbara Cosimelli, et al.
Published: (2019-01-01)